Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

<p>Supplementary Table S8. DEGs for 6 months Comparison of CD49d+ and CD49d-</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Anfal Alsadhan (15907475) (author)
Drugi avtorji:	Jonathan Chen (15907478) (author), Erika M. Gaglione (15032498) (author), Chingiz Underbayev (15907481) (author), Pamela L. Tuma (15907484) (author), Xin Tian (15907487) (author), Lita A. Freeman (15907490) (author), Sivasubramanian Baskar (15907493) (author), Pia Nierman (15907496) (author), Susan Soto (15907499) (author), Andy Itsara (15907502) (author), Inhye E. Ahn (15032501) (author), Clare Sun (14953020) (author), Elena Bibikova (15907505) (author), Tanja Nicole Hartmann (15907508) (author), Maissa Mhibik (15907511) (author), Adrian Wiestner (15907514) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Immuno-oncology Cell Signaling Cell adhesion Protein tyrosine kinases Drug Resistance Hematological Cancers Leukemias Lymphomas Immunology Immunomodulation
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
od: Anfal Alsadhan (15907475)
Izdano: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
od: Zhihang Chen (17315678)
Izdano: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
od: Xinhang Gu (22686224)
Izdano: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
od: Ruth Flümann (15123900)
Izdano: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
od: Snehanshu Chowdhury (14957031)
Izdano: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
od: Upendra Kumar Soni (15051683)
Izdano: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
od: Ti Wen (15130158)
Izdano: (2025)

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
od: Nan Ding (15321526)
Izdano: (2025)

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
od: Nan Ding (15321526)
Izdano: (2025)

Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
od: Xiaojuan Li (351842)
Izdano: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Izdano: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Izdano: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
od: Erika Y. Faraoni (14844897)
Izdano: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
od: Francesco Maura (15022226)
Izdano: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Izdano: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
od: Jonathan M.J. Derry (16648337)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8vb99go92anibaqlokmm7f84e7